AstraZeneca Pharma India has taken a significant step in its site exit strategy by surrendering its manufacturing license, marking the end of its manufacturing operations in India. The pharmaceutical company has voluntarily relinquished the license, which was originally valid until December 2027, ahead of its expiration date.

Manufacturing License Surrender

According to a regulatory filing dated September 2, 2025, AstraZeneca Pharma India Limited has officially surrendered its manufacturing license to the Drugs Controller and Licensing Authority for cancellation. This move is in line with the company's previously announced exit strategy for its manufacturing site in India.

The company stated in its filing, "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our intimation to stock exchanges on June 21, 2024, regarding the exit from our manufacturing site, we wish to inform you that AstraZeneca Pharma India Limited ('the Company') has surrendered its manufacturing license, which was valid up to December 2027, to the Drugs Controller and Licensing Authority for cancellation."

Background and Timeline

The decision to exit manufacturing operations in India appears to have been in the works for some time. The company had previously informed stock exchanges about its plans to exit the manufacturing site on June 21, 2024. This latest development represents the culmination of that strategy, with the company now formally surrendering its manufacturing license.

ESG Rating Disclosure

In a separate but noteworthy development, AstraZeneca Pharma India also disclosed its Environmental, Social, and Governance (ESG) rating in a filing dated September 1, 2025. Crisil ESG Ratings & Analytics Limited has assigned an ESG rating of 58.00 to the company based on publicly available information for the fiscal period 2025.

The company clarified that it had not engaged Crisil ESG Ratings for this assessment, stating, "Please note that the Company has not engaged Crisil ESG Ratings. They have independently prepared the report based on publicly available information."

This ESG rating disclosure aligns with the company's compliance with SEBI regulations and demonstrates its commitment to transparency in environmental, social, and governance matters.

As AstraZeneca Pharma India moves forward with these strategic decisions, stakeholders will be watching closely to see how these changes impact the company's operations and market position in India's pharmaceutical landscape.

AstraZeneca Pharma India Limited, a prominent player in the pharmaceutical sector, has reported a strong financial performance for the first quarter, marking a significant turnaround from the previous year.

Financial Highlights

The company's total income from operations soared to Rs. 5,375.50 million, representing a substantial 35.8% increase from Rs. 3,958.70 million in the corresponding quarter of the previous year. This impressive growth in revenue underscores the company's strong market position and effective business strategies.

In a remarkable turnaround, AstraZeneca Pharma India posted a net profit after tax of Rs. 558.30 million, compared to a loss of Rs. 117.90 million in the same quarter last year. This shift from loss to profit demonstrates the company's improved operational efficiency and cost management.

The earnings per share (EPS) saw a dramatic improvement, reaching Rs. 22.33, up from a loss per share of Rs. 4.72 in the previous year. This significant increase in EPS reflects the company's enhanced profitability and potential value for shareholders.

Key Financial Metrics

Operational Changes

During the quarter, AstraZeneca Pharma India made a strategic decision to cease operations at its manufacturing site and commence plant decommissioning. As a result, the plant and machinery related to the manufacturing site have been fully depreciated. This move is likely part of the company's efforts to optimize its operations and improve overall efficiency.

Corporate Governance

The financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on August 14. The statutory auditors of the company have carried out a limited review of the financial results, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.

Annual General Meeting

AstraZeneca Pharma India Limited held its 46th Annual General Meeting (AGM) on August 14 through video conferencing. All resolutions mentioned in the AGM notice were duly passed by the company's members with the requisite majority, as confirmed by the scrutinizer's report dated August 18.

AstraZeneca Pharma India's strong Q1 performance, coupled with strategic operational changes, positions the company favorably in the competitive pharmaceutical landscape. Investors and industry observers will likely keep a close watch on how these positive results and operational shifts translate into long-term growth and sustainability for the company.